Filing Details
- Accession Number:
- 0000908662-17-000058
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-03-02 16:08:16
- Reporting Period:
- 2017-02-28
- Filing Date:
- 2017-03-02
- Accepted Time:
- 2017-03-02 16:08:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528557 | Corindus Vascular Robotics Inc. | CVRS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1519465 | C Jeffrey Lightcap | 152 W. 57Th Street, 43Rd Floor New York NY 10019 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-02-28 | 7,557,436 | $0.66 | 32,500,478 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnote |
Footnotes
- Consists of 17,090,941 shares held directly by HealthCor Partners Fund, L.P. ("HCP") and 15,409,537 shares held directly by HealthCor Partners Fund II, L.P. ("HCPII"). The shares held by HCP may be deemed to be beneficially owned by HealthCor Partners, L.P. ("HCPLP"), its general partner, and by HealthCor Partners GP, LLC ("HCPGP"), the general partner of HCPLP. The shares held by HCPII may be deemed to be beneficially owned by HealthCor Partners II, L.P. ("HCP2LP"), its general partner, and by HCPGP, the general partner of HCP2LP. Mr. Lightcap is a managing member of HCPGP and may be deemed to have shared voting and investment power over such shares. Each of HCPLP, HCP2LP, HCPGP and Mr. Lightcap hereby disclaims any beneficial ownership of shares held by HCP or HCPII except to the extent of any pecuniary interest therein. The record and other beneficial owners have separately filed a Form 4 to reflect the acquisition by HCPII.